We have located links that may give you full text access.
MicroRNA‑214 promotes the EMT process in melanoma by downregulating CADM1 expression.
Molecular Medicine Reports 2020 November
Melanoma is a malignant skin cancer type associated with a high mortality rate, but its treatment is currently not ideal. Both microRNA (miR)‑214 and cell adhesion molecule 1 (CADM1) are differentially expressed in melanoma, but their role in this cancer type remains unknown. Therefore, the aim of the present study was to investigate the role of CADM1 and miR‑214 in melanoma to identify novel targets for its treatment. The expression levels of CADM1 and miR‑214 in cells were detected by reverse transcription‑quantitative PCR (RT‑qPCR). Moreover, cell viability, migration and invasion were measured by MTT, wound healing and Transwell assays, respectively. In addition, the relative expression levels of epithelial‑mesenchymal transition (EMT)‑related proteins in cells were detected by RT‑qPCR and western blotting. It was found that the expression of CADM1 was inhibited in melanoma cells, while miR‑214 expression was increased during melanoma tumorigenesis. Furthermore, miR‑214 mimics promoted the viability, migration and invasion of melanoma cells. It was also demonstrated that the downregulation of CADM1 reversed the inhibitory effect of the miR‑214 inhibitor in melanoma. Moreover, overexpression of CADM1 inhibited the EMT process in melanoma, while the miR‑214 inhibitor suppressed the EMT process. The results also indicated that miR‑214 promoted the EMT process by downregulating CADM1, which may represent a novel mechanism for the progression of melanoma.
Full text links
Related Resources
Trending Papers
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.Circulation 2024 May 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app